Taeniasis

What is taeniasis and cysticercosis?

Diagnosis and treatment

Diagnosis

Improved, simple, cost-effective and rapid diagnostic tools are still needed for use in field conditions to detect T. solium carriers as well as human and porcine cysticercosis cases, and to direct programme planning and monitoring. WHO and partners are addressing the lack of a suitable diagnostic toolbox by developing standards for diagnostic products tailored to the needs in countries and especially field settings.

Treatment

Taeniasis can be treated with praziquantel (5–10 mg/kg, single-administration) or niclosamide (adults and children over 6 years: 2 g, children aged 2–6 years: 1 g; children under 2 years: 500 mg, single-administration after a light meal followed after 2 hours by a laxative).

Currently, clinical management and treatment guidelines for neurocysticercosis are being developed by an expert panel with secretariat in WHO. So far, treatment has to be tailored to the individual case. Treatment of active disease may include surgery and/or long courses with praziquantel and/or albendazole, as well as supporting therapy with corticosteroids and/or anti-epileptic drugs, since the destruction of cysts may lead to an inflammatory response. The dosage and the duration of treatment can vary greatly and depend mainly on the number, size, location and developmental stage of the cysts, their surrounding inflammatory edema, acuteness and severity of clinical symptoms or signs.

Further reading